This article reviews the latest pharmaceutical forecasts from IQVIA's Market Prognosis, offering an overview of the key opportunities and challenges anticipated to impact the Nordic pharmaceutical markets over the next five years. The analysis is based on findings from Denmark, Finland, Norway, and Sweden, as detailed in the IQVIA Market Prognosis September 2024 edition.

Amid ongoing geopolitical tensions, global pharmaceutical sales growth is projected to slow, with aggregate growth (in US dollars at constant exchange rates) forecast to reach 8.8% in 2024, down from 10.3% in 2023. Global pharmaceutical sales are forecast to post a compound annual growth rate (CAGR) of 7.4% over 2023–2028, compared to 7.5% over 2018–2023. Combined, the four Nordic pharmaceutical markets are forecast to grow strongly at 9.0% in 2024. However, growth is forecast to decelerate to a CAGR of 6.4% over 2023-2028, slower than the other European (EU and non-EU) countries, and below the global average.

Read the full article to explore the future of Nordic pharmaceuticals! Discover key opportunities and challenges with insights from IQVIA's Market Prognosis. Learn about the impact of geopolitical tensions, the growth of specialty and anti-obesity drugs, and innovative strategies to enhance drug availability.